AHL
LGND icon

Abel Hall LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Abel Hall LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373K Buy
1,181
+69
+6% +$16.3K 0.06% 370
2026
Q1 		$222K Buy
+1,112
New +$220K 0.05% 563

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Abel Hall LLC's LGND Position: Q2 2026 in Review

Abel Hall LLC increased its Ligand Pharmaceuticals (LGND) stake by 6.2% in Q2 2026, buying an estimated $16.3K and bringing the position to 1,181 shares worth $373K. The position accounts for 0.06% of the portfolio, ranked #370.

Abel Hall LLC first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Abel Hall LLC held 1,181 shares of Ligand Pharmaceuticals worth $373K as of Q2 2026.
  • Abel Hall LLC bought 69 Ligand Pharmaceuticals shares in Q2 2026, an estimated $16.3K.
  • Ligand Pharmaceuticals made up 0.06% of Abel Hall LLC's portfolio in Q2 2026, its #370 holding.
  • Abel Hall LLC first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.